Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 28
ERK plays a conserved dominant role in pancreas cancer cell EMT heterogeneity driven by diverse growth factors and chemotherapies
Michelle C. Barbeau, Brooke A. Brown, Sara J. Adair, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access | Times Cited: 1
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies
Alaa Y. Bazeed, Candace M. Day, Sanjay Garg
Cancers (2022) Vol. 14, Iss. 17, pp. 4257-4257
Open Access | Times Cited: 33
PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial
Juan Du, Changchang Lu, Liang Mao, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 3, pp. 100972-100972
Open Access | Times Cited: 18
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Antonin Lévy, Daphné Morel, Matthieu Texier, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Recent Advances and Challenges in Stereotactic Body Radiotherapy
Atsuto Katano, Masanari Minamitani, Shingo Ohira, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access | Times Cited: 6
Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?
Roger Sun, Théophraste Henry, Adrien Laville, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 7, pp. e004848-e004848
Open Access | Times Cited: 25
TGF-β Signaling in Progression of Oral Cancer
Yuanyuan Guo, Tiansong Xu, Yujuan Chai, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10263-10263
Open Access | Times Cited: 14
Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
Sofian Benkhaled, Cedric Peters, Nicolas Jullian, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 768-768
Open Access | Times Cited: 13
Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application
François Ghiringhelli, Cédric Rébé
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 335-349
Open Access | Times Cited: 12
Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy
Han Zhang, Wenjin Xu, Haitao Zhu, et al.
Journal of Cancer (2024) Vol. 15, Iss. 7, pp. 2003-2023
Open Access | Times Cited: 4
Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib
Junyeol Kim, Tae Seung Lee, Myeong Hwan Lee, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 1056-1056
Open Access | Times Cited: 4
Challenges and Opportunities for the Clinical Application of the Combination of Immune-Checkpoint Inhibitors and Radiation Therapy in the Treatment of Advanced Pancreatic Cancer
Masashi Kanai
Cancers (2025) Vol. 17, Iss. 4, pp. 606-606
Open Access
Pancreatic cancer: failures and hopes—a review of new promising treatment approaches
Vittore Cereda, Mario D’Andrea
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Innovative, early-phase clinical trials of drug–radiotherapy combinations
Antonin Lévy, Christophe Massard, Stefan Michiels, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 4, pp. e190-e202
Closed Access
Pancreatic Cancer: Pathogenesis and Clinical Studies
Kexun Zhou, Yingping Liu, Chuanyun Tang, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Pancreatic cancer
Thomas F. Stoop, Ammar A. Javed, Atsushi Oba, et al.
The Lancet (2025) Vol. 405, Iss. 10485, pp. 1182-1202
Closed Access
The Immunoradiotherapy in HNSCC
Tao Zhang, Wei Du, S.D. Zhang, et al.
(2025), pp. 53-107
Closed Access
Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity
Shengbo Wu, Weichen Xu, Xuexia Shan, et al.
Advanced Science (2025)
Open Access
Treatment for postoperative recurrence of pancreatic cancer: a narrative review
Takuji Okusaka
Chinese Clinical Oncology (2022) Vol. 11, Iss. 3, pp. 19-19
Open Access | Times Cited: 16
Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives
A. Helm, C. Totis, Marco Durante, et al.
International review of cell and molecular biology (2023), pp. 1-36
Closed Access | Times Cited: 9
New Treatment Options in Metastatic Pancreatic Cancer
Marta Fudalej, Daria Kwaśniewska, Paweł Nurzyński, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2327-2327
Open Access | Times Cited: 9
Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top